Corbus Pharma

Corbus (Nasdaq: $CRBP) is connecting innovation to purpose to improve the futures of cancer and obesity patients.

[Corbus Pharma @CorbusPharma]

Preclinical data suggests CRB-913 may significantly amplify the effectiveness of semaglutide and tirzepatide, offering sustained weight loss without excess muscle mass loss or neuropsychiatric effects. Learn more: https://t.co/LARNJQJoWB

[Corbus Pharma @CorbusPharma]

Overactivated CB1 receptors have been shown to drive excess hunger, fat storage, & insulin resistance seen in #obesity. CRB-913 is designed to selectively block peripheral CB1 activity, targeting obesity at its biological root without CNS side effects. https://t.co/LARNJQJoWB

[Corbus Pharma @CorbusPharma]

"I'm delighted to join Corbus at a time of notable evolution for the Company," said newly appointed Chief Medical Officer, Leonardo Viana Nicacio, M.D. Corbus is advancing toward multiple near-term potential milestones, learn more: https://t.co/EPCJ1tsRsR $CRBP

[Corbus Pharma @CorbusPharma]

"We're thrilled to welcome Dr. Nicacio to Corbus, particularly as we approach initiation of our TEMPO-1 registrational study of CRB-701 in 2L OPSCC this summer," said @CEOCorbus on the appointment of Dr. Nicacio, M.D. as Chief Medical Officer: https://t.co/EPCJ1tsRsR $CRBP

[Corbus Pharma @CorbusPharma]

Corbus today announced the appointment of Leonardo Viana Nicacio, M.D. as Chief Medical Officer. Dr. Nicacio brings 20+ years in pharma, including a pivotal role advancing TIVDAK® to market for metastatic cervical cancer. Read more: https://t.co/EPCJ1tsRsR $CRBP

[Corbus Pharma @CorbusPharma]

CRB-913 is a second-generation, orally administered CB1 inverse agonist in development for the treatment of #obesity. Designed with minimal brain penetration, CRB-913 targets peripheral CB1 receptors to potentially promote weight loss. Learn more: https://t.co/LARNJQJoWB

[Corbus Pharma @CorbusPharma]

In an interview with the Molecules and Minerals podcast, @CEOCorbus discussed updated data from the Ph. 1/2 study of CRB-701, Corbus' strategic focus on HPV+ oropharyngeal squamous cell carcinoma (OPSCC), and upcoming potential catalysts: https://t.co/YvK810IUpK $CRBP

[Steven H. Goldman @Steven38199694]

Oral sex is the leading cause of HPV driven throat cancer (oropharyngeal squamous carcinoma) which is a rapidly increasing cancer in US. This is one topic discussed in my recent podcast interview with Corbus CEO Yuval Cohen. See link below. $CRBP @CEOCorbus @CorbusPharma Corbus: Potentially Best-in-Class Treatment for HPV-Driven Oropharyngeal... https://t.co/FyCg0icJWr via @YouTube

[Corbus Pharma @CorbusPharma]

@CEOCorbus will present a corporate overview today, June 4th, at 4:55 EDT at the Jefferies Global Healthcare Conference. Watch the webcast here: https://t.co/FRw4vf1WZa $CRBP

[Corbus Pharma @CorbusPharma]

Tune-in on Thursday, June 4th at 4:55pm EDT for @CEOCorbus's presentation at the Jefferies Global Healthcare Conference. For webcast details: https://t.co/FRw4vf1WZa $CRBP

[Corbus Pharma @CorbusPharma]

Tune-in tomorrow, June 1st for our #HNSCC KOL event at #ASCO26—updated Phase 1/2 data for CRB-701 including clinical response durability and subgroup analysis, with expert discussion from @AriRosenbergMD, @HeadNeckMD and @CesarAPerezMD. Register here: https://t.co/QNmWnMHynU

[Corbus Pharma @CorbusPharma]

Reminder: An abstract featuring updated data from Corbus' Phase 1/2 study CRB-701 in patients with recurrent or metastatic #HNSCC will be presented at #ASCO26 today, May 30th at 4:30 PM CDT (Abstract 6062). For more info: https://t.co/oPKK7pQ3ID

#OPSCC $CRBP

[Corbus Pharma @CorbusPharma]

We look forward to sharing updated CRB-701 data in #HNSCC at #ASCO26 and discussing them on June 1st at our in-person and virtual KOL event with leading experts @AriRosenbergMD, @HeadNeckMD, and @CesarAPerezMD. Register: https://t.co/QNmWnMHynU

[Corbus Pharma @CorbusPharma]

Attending #ASCO26? An abstract featuring updated data from Corbus' Phase 1/2 study CRB-701 in patients with recurrent or metastatic #cervicalcancer will be presented tomorrow, May 29th at 4:57 PM CDT (Abstract 5508). For more info: https://t.co/oPKK7pQ3ID $CRBP

[Corbus Pharma @CorbusPharma]

Join us on Monday, June 1st for a KOL event to discuss updated data from the Phase 1/2 clinical study of CRB-701 featuring insights from leading #HNSCC experts: @AriRosenbergMD, @HeadNeckMD and @CesarAPerezMD

Register here: https://t.co/QNmWnMHynU

#ASCO26 #OPSCC $CRBP

[Corbus Pharma @CorbusPharma]

ICYMI - Glenn Hanna, M.D. (@HeadNeckMD) joined @CEOCorbus to discuss updated CRB-701 data being presented at #ASCO26 which affirms Corbus's strategy of targeting tumor types with elevated Nectin-4 expression & clear unmet medical needs. Listen here: https://t.co/C12MTsyGHc $CRBP

[Corbus Pharma @CorbusPharma]

Thank you @bradloncar of @BiotechTV for speaking with @CEOCorbus about our updated CRB-701 Ph. 1/2 clinical data being presented at #ASCO26 which demonstrated robust activity in 2L oropharyngeal & #cervicalcancers. Watch the interview: https://t.co/nSObkbhNcI $CRBP #HNSCC #OPSCC

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Ahead of ASCO, @CorbusPharma is providing updated data today on its Nectin-4 ADC in cervical and head and neck cancer - @CEOCorbus describes how response rate appears to be directly related to HPV status. $CRBP

Full video: https://t.co/8JnpGk7JYC

[Corbus Pharma @CorbusPharma]

"These data provide important clarity on the clinical and commercial path for CRB-701 in 2L oropharyngeal and cervical cancers," – @CEOCorbus. Read more about the updated CRB-701 Phase 1/2 clinical data: https://t.co/0ZtkIqZJn6

$CRBP #OPSCC #CervicalCancer #ASCO26

[Corbus Pharma @CorbusPharma]

Corbus reported updated data from its Ph. 1/2 study of CRB-701 demonstrating robust activity in 2L oropharyngeal squamous cell carcinoma & #CervicalCancer. Management will host a webcast today, May 26 at 8 am EDT to discuss the data. Details: https://t.co/0ZtkIqZJn6 $CRBP #ASCO26

[Corbus Pharma @CorbusPharma]

Tune-in tomorrow, May 26th at 8 a.m. EDT for our conference call and webcast discussing data for the Phase 1/2 study of CRB-701 in both #HNSCC as well as #CervicalCancer, which will be presented at #ASCO26. For webcast details: https://t.co/C12MTsyGHc $CRBP

[Corbus Pharma @CorbusPharma]

Join us on Tues., May 26th at 8 a.m. EDT for a conference call and webcast where Corbus management will discuss the data for the Phase 1/2 study of CRB-701 in both #HNSCC and #CervicalCancer, which will be presented at #ASCO26. For details: https://t.co/C12MTsyGHc $CRBP